Citadel Advisors
EVMN

Citadel Advisors’s Evommune Inc EVMN Stock Holding History

Citadel Advisors’s Portfolio EVMN Stock Details EVMN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-50,560
Closed -$866K – 14829
2025
Q4 		$866K Buy
+50,560
New +$950K ﹤0.01% 7721

Other funds holding EVMN

EFM
EQT Fund Management Luxembourg $1.02B AUM
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
PBPIA
Pivotal bioVenture Partners Investment Advisor San Francisco, California $280M AUM 181.4% 1-Year Est. Return
AP
Andera Partners Paris $206M AUM
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
NFGH
Nan Fung Group Holdings Kai Tak, Hong Kong $121M AUM 56.89% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
SCP
SymBiosis Capital Partners Bentonville, Arkansas $52.8M AUM
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Citadel Advisors's EVMN Position: Q1 2026 in Review

Citadel Advisors sold out of Evommune Inc (EVMN) in Q1 2026, closing a stake of 50,560 shares — an estimated $866K sold.

Citadel Advisors first reported a position in EVMN in Q4 2025 and held it in 1 quarter. The position peaked at $866K in Q4 2025. 84 funds tracked by Wall St. Rank hold EVMN as of Q1 2026.

  • Citadel Advisors reported no remaining Evommune Inc position as of Q1 2026 after selling out during the quarter.
  • Citadel Advisors sold 50,560 Evommune Inc shares in Q1 2026, an estimated $866K.
  • Citadel Advisors first reported a position in Evommune Inc in Q4 2025 and held it in 1 quarter.
  • Citadel Advisors's Evommune Inc position peaked at $866K in Q4 2025.
  • 84 funds tracked by Wall St. Rank held Evommune Inc as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.